The central focus of the Cytogenetics Shared Resource (CYT) is to provide high quality cytogenetic and molecular cytogenetic analysis of human and animal model research samples in a timely, cost-effective manner for members of the Mayo Clinic Cancer Center (MCCC) and other investigators within the Mayo research community. External requests are accommodated with discretion. The highly specialized cytogenetic and molecular cytogenetic services and equipment utilized to provide such services to MCCC users would be impractical to institute into multiple individual laboratories. These services are ideally provided in a central location and in a Shared Resource environment, which eliminates the need to duplicate expensive equipment and technologist training and analysis time. Services within the CYT include: Cell Culture, Routine Chromosome Analysis, DNA and RNA fluorescence in situ Hybridization (FISH), and Custom DNA Probe Production as well as RNA FISH Probe Production and a Tyramide Signal Amplification (TSA) protocol. Together, with the investigator, the CYT assists in determining how these techniques can be utilized to meet the evolving needs of their research studies. In addition to the test menu described above, the CYT staff also provides specialized training to investigators for FISH set-up, and microscope use in an effort to minimize investigator cost and economize technologist time. The staff that makes up the CYT have over 75 years of combined cytogenetic and molecular cytogenetic expertise. The capability provided by the CYT is not present in any other Shared Resource facility or research laboratory at Mayo Clinic. The 6 highly qualified and experienced staff members (3.6 FTE) provide expert consultation in experimental design, troubleshooting, modification of experiments, and interpretation of results. The staff also serves to help facilitate the translation of molecular cytogenetic discoveries into clinically available diagnostic assays. In the past grant cycle (2013- 2017), the CYT had a total of 208 users, representing 10 of the 10 MCCC Programs active at the time. Among our 208 users, 84 (40.4%) are MCCC members. Of these 84 investigators, 57 (68%) have active peer- reviewed funding. During these past 5 years, the CYT supported the production of 36 peer-reviewed publications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications